Back to results
US 7,459,282 B2Granted
Use of c-Jun or c-Jun activating agents such as UV or c-Jun N-terminal kinases (JNKs) for treating cancer
AssigneeBiotech Research Ventures Pte Limited
InventorKanaga Sabapathy
Life of this patent
Estimating the term…
Abstract
The invention concerns the increased stabilization and activation of p73, a homologue of p53. Specifically, the inventors have determined that c-Jun, a component of the AP-1 family of transcription factors, is necessary for stabilization and activation of p73. Thus, there is provided a mechanism for initiating an apoptotic pathway involving c-June and p73 which can be exploited to combat cancers, particularly those lacking a functional p53.
Claims11
A method of screening for substances that are capable of mimicking the activity of c-Jun in stabilizing or activating p73, said method comprising:
- a) contacting a first reaction medium comprising a c-Jun−/− cell capable of expressing p73 said cell comprising a nucleic acid construct comprising a p73 binding site linked to a reporter gene,
- b) determining and comparing reporter gene expression level in a comparable second reaction medium untreated with the test substance, a test substances which alters reporter gene expression levels in the cells of step a) compared to the cells in step b) being identified as a stabilizer or activator of p73.
Dependencies are inferred from the claim text.